Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and pathologic response of neoadjuvant pulsed electric field ablation and systemic therapy in early-stage resectable lung cancer: case series.

Journal of thoracic disease·2026
Same author

Reply to: "Beyond Response Rates: Interpreting Long-Term Benefit in CheckMate 743" and "Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743".

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, <i>EGFR</i> Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial.

JTO clinical and research reports·2026
Same author

Overlapping gut microbiome signatures in aging and disease are characterized by enrichment of medication-associated oral microbes in the gut.

FEBS letters·2026
Same author

Identification of tumor-associated antigens with multi-cancer therapeutic potential.

Frontiers in immunology·2026
Same author

Amivantamab induces immune-mediated cytotoxicity in mesothelioma via EGFR and MET engagement.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Related Experiment Video

Updated: May 7, 2025

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

8.5K

Individualized Cell-Free DNA Monitoring With Chromosomal Junctions for Mesothelioma.

Kaushal Parikh1, Faye R Harris1, Giannoula Karagouga1

  • 1Mayo Clinic, Rochester, Minnesota.

JTO Clinical and Research Reports
|December 30, 2024
PubMed
Summary

This study developed a blood test using cell-free DNA (cfDNA) to monitor mesothelioma by detecting unique chromosomal rearrangements. The personalized assay showed promising results in detecting circulating tumor DNA (ctDNA) and correlating with disease status.

Keywords:
Cell-free DNAChromosomal rearrangementsMesothelioma

More Related Videos

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
08:25

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

10.8K
Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

3.8K

Related Experiment Videos

Last Updated: May 7, 2025

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

8.5K
Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
08:25

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

10.8K
Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

3.8K

Area of Science:

  • Oncology
  • Genetics
  • Molecular Diagnostics

Background:

  • Mesothelioma diagnosis and monitoring are challenging due to complex spatial characteristics and limitations of current cell-free DNA (cfDNA) strategies.
  • Existing cfDNA monitoring methods are insufficient for mesothelioma because of limited recurring somatic variants.
  • Patient-specific chromosomal rearrangements are a common feature in mesothelioma, offering a potential target for monitoring.

Purpose of the Study:

  • To develop an individualized cfDNA assay for blood-based monitoring of mesothelioma using circulating tumor DNA (ctDNA).
  • To investigate the utility of unique chromosomal rearrangement junctions for personalized ctDNA detection and disease surveillance in mesothelioma patients.

Main Methods:

  • Whole genome sequencing of tumor DNA to identify chromosomal junctions.
  • Prioritization of junctions based on allele frequency and genomic homology.
  • Design of personalized junction panels with primers and probes for quantitative PCR.
  • Testing of patient plasma for personalized junctions using quantitative PCR.

Main Results:

  • Identified 763 chromosomal junctions across nine mesothelioma patients (five pleural, four peritoneal).
  • Successfully detected selected junctions in the plasma of 78% of patients (7/9).
  • Detected cell-free DNA junctions correlated with disease status, showing presence in persistent disease and absence in disease remission.

Conclusions:

  • Individualized ctDNA junction assays show potential for mesothelioma monitoring.
  • This approach could complement existing imaging techniques for disease surveillance.
  • Further validation is needed to establish the clinical utility of this personalized cfDNA assay.